𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Effects of imatinib mesylate on normal bone marrow cells from chronic myeloid leukemia patients in complete cytogenetic response

✍ Scribed by Fermin M. Sanchez-Guijo; Jesus M. Hernandez; Eva Lumbreras; Patricia Morais; Carlos Santamaría; Juan-Luis Garcia; Norma C. Gutierrez; Jesus F. San Miguel; Maria-Consuelo del Cañizo

Publisher
Elsevier Science
Year
2009
Tongue
English
Weight
418 KB
Volume
33
Category
Article
ISSN
0145-2126

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of imatinib in patie
Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-α
✍ Susan Branford; Timothy Hughes; Alvin Milner; Rachel Koelmeyer; Anthony Schwarer 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 201 KB 👁 2 views

## Abstract ## BACKGROUND. Interferon‐alpha (IFN‐α) confers a survival advantage for the minority of patients with chronic myeloid leukemia (CML) who achieve a complete cytogenetic response. The question of whether IFN‐α‐responsive patients can experience further improvements with imatinib has not

Prediction of initial cytogenetic respon
Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia
✍ Hagop Kantarjian; Moshe Talpaz; Susan O'Brien; Francis Giles; Mary Beth Rios; Ke 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB 👁 1 views

## Abstract ## BACKGROUND Obtaining a major (Philadelphia chromosome [Ph] of < 35%) or a complete cytogenetic response (Ph of 0%) has been associated with excellent long‐term survival. Cytogenetic response may continue to improve with therapy. Because early allogeneic stem cell transplantation (SC